The need to manage the risk of thromboembolism in COVID-19 patients.
Level V
Where this comes from
- Record sourced from PubMed, PMID 32417304.
- Also identified by DOI 10.1016/j.jvs.2020.05.015 and PMC identifier 7224653.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
COVID-19 first appeared in Wuhan, Hubei Province, China, in December 2019. Thought to be of zoonotic origin, it has been named SARS-CoV-2 (COVID-19) and has spread rapidly. As of April 20, 2020, there have been >2.4 million cases recorded worldwide. The inflammatory process, cytokine storm, and lung injury that are associated with COVID-19 can put patients at an increased risk of thrombosis. The total incidence of thrombotic events in COVID-19 patients is currently uncertain. Those with more severe disease and with other risk factors, including increasing age, male sex, obesity, cancer, comorbidities, and intensive care unit admission, are at higher risk of these events. However, there is little international guidance on managing these risks in COVID-19 patients. In this paper, we explore the current evidence and theories surrounding thrombosis in these unique patients and reflect on experience from our center.
Medical subject headings
- Anticoagulants
- Betacoronavirus
- Coronavirus Infections
- Cytokine Release Syndrome
- Pneumonia, Viral
- Thromboembolism